Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	Torin2	2	72	sigmoid	sigmoid	HCC38 Torin2 0 2 72	8	2.140	0.0146	-0.48	0.793	0.0654	-0.634	0.545	0.993	3.78e-07	NA	0.0176	0.056	0.391	0.015	0.0502	0.68	0.989	1.33e-06	NA
BT-20	AS605240	1	72	sigmoid	sigmoid	BT20 AS-605240 0 1 72	8	2.142	Inf	0.817	0.0993	3.91	0.634	0.244	0.861	0.00271	NA	Inf	0.814	0.897	3.87	0.629	0.237	0.854	0.00311	NA
HCC38	Buparlisib	2	72	sigmoid	sigmoid	HCC38 buparlisib 0 2 72	8	2.142	0.876	-0.185	0.172	1.24	-0.413	1.74	0.996	5.03e-08	NA	0.959	0.146	0.861	0.893	0.0606	1.8	0.992	4.3e-07	NA
HCC38	WYE-125132	2	72	sigmoid	sigmoid	HCC38 WYE-132 0 2 72	8	2.143	0.0568	0.149	0.473	0.0413	0.124	0.896	0.998	9.66e-09	NA	0.078	0.305	0.587	0.0297	0.285	0.875	0.997	1.58e-08	NA
HCC38	CAL-101	2	72	sigmoid	sigmoid	HCC38 idelalisib 0 2 72	8	2.154	Inf	0.881	0.0205	0.901	0.879	3.37	0.892	0.00125	NA	Inf	0.876	0.979	0.891	0.874	3.37	0.887	0.00144	NA
HCC38	GDC-0980	2	72	sigmoid	sigmoid	HCC38 apitolisib 0 2 72	8	2.159	0.33	0.153	0.279	0.253	0.117	1.0	0.992	4.91e-07	NA	0.385	0.304	0.749	0.165	0.308	1.13	0.994	2.09e-07	NA
HCC38	MK2206	2	72	sigmoid	sigmoid	HCC38 MK-2206 0 2 72	8	2.159	Inf	0.788	0.0476	0.776	0.775	1.99	0.972	2.1e-05	NA	Inf	0.785	0.951	0.752	0.772	1.98	0.969	2.9e-05	NA
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC38	BX-912	2	72	sigmoid	sigmoid	HCC38 BX-912 0 2 72	8	2.186	0.583	-0.229	0.251	0.648	-0.233	3.62	0.999	9.58e-10	NA	0.602	0.124	0.807	0.559	0.123	3.78	0.998	1.03e-08	NA
BT-20	BX-912	1	72	flat	flat	BT20 BX-912 0 1 72	8	2.193	Inf	0.858	0.0928	0.0	0.858	0.01	0.25	0.422	0.903	Inf	0.851	0.901	0.0	0.851	0.01	0.243	0.433	0.897
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965
HCC38	AS605240	2	72	sigmoid	sigmoid	HCC38 AS-605240 0 2 72	8	2.200	17.4	0.642	0.114	4.07	0.256	0.493	0.936	0.000265	NA	46.2	0.648	0.882	1.68	0.411	0.522	0.929	0.000356	NA
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
HCC38	ZSTK474	2	72	sigmoid	sigmoid	HCC38 ZSTK474 0 2 72	8	2.253	1.63	0.396	0.196	2.18	-0.0865	0.554	0.984	4.3e-06	NA	2.0	0.445	0.803	1.14	0.135	0.556	0.982	5.91e-06	NA
HCC70	MK2206	3	72	sigmoid	sigmoid	HCC70 MK-2206 0 3 72	8	2.378	1.43	0.423	0.139	0.451	0.39	1.31	0.983	5.28e-06	NA	1.47	0.445	0.859	0.349	0.437	1.44	0.977	1.2e-05	NA
HCC70	Everolimus	3	72	sigmoid	sigmoid	HCC70 everolimus 0 3 72	8	2.401	530906.0	0.749	0.195	0.072	0.603	0.1	0.706	0.0255	NA	381983.0	0.725	0.782	0.0137	0.59	0.1	0.706	0.0255	NA
HCC70	Torin1	3	72	sigmoid	sigmoid	HCC70 Torin1 0 3 72	8	2.415	3.74	0.495	0.279	0.0352	0.496	1.02	0.994	2.6e-07	NA	5.73	0.495	0.709	0.0284	0.498	1.06	0.994	2.26e-07	NA
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA
BT-20	Dactolisib	3	72	sigmoid	sigmoid	BT20 dactolisib 0 3 72	8	2.420	0.0111	0.024	0.639	0.00921	0.0987	1.17	0.982	6.27e-06	NA	0.0106	0.198	0.427	0.00645	0.241	1.32	0.99	9.14e-07	NA
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.0	0.478	0.01	0.561	0.0844	0.534
HCC70	GDC-0980	3	72	sigmoid	sigmoid	HCC70 apitolisib 0 3 72	8	2.423	0.623	0.206	0.211	0.509	0.0878	0.959	0.986	2.55e-06	NA	0.568	0.293	0.792	0.283	0.266	1.09	0.981	6.41e-06	NA
HCC70	Torin2	3	72	sigmoid	sigmoid	HCC70 Torin2 0 3 72	8	2.425	0.076	-0.384	0.567	0.532	-0.933	0.541	0.988	1.88e-06	NA	0.0694	0.0576	0.51	0.0694	0.0	0.61	0.973	2.02e-05	NA
HCC70	Dactolisib	3	72	sigmoid	sigmoid	HCC70 dactolisib 0 3 72	8	2.430	0.738	0.321	0.312	18.6	-0.818	0.3	0.975	1.64e-05	NA	0.688	0.365	0.675	0.635	0.0134	0.338	0.97	2.7e-05	NA
HCC70	Buparlisib	3	72	sigmoid	sigmoid	HCC70 buparlisib 0 3 72	8	2.439	0.968	-0.156	0.167	1.7	-0.624	1.43	0.995	1.16e-07	NA	0.944	0.122	0.852	0.944	0.0	1.57	0.988	1.57e-06	NA
HCC70	AZD8055	3	72	sigmoid	sigmoid	HCC70 AZD8055 0 3 72	8	2.442	Inf	0.571	0.287	0.0133	0.574	1.17	0.98	8.55e-06	NA	Inf	0.554	0.694	0.0116	0.556	1.17	0.974	1.69e-05	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)